A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Liverpool Hospital /ID# 244826, Liverpool

St. Vincent's Private Hospital Melbourne /ID# 262631, Fitzroy

St Vincent's Hospital Melbourne /ID# 244827, Fitzroy Melbourne

Austin Health and Ludwig Institute for Cancer Research /ID# 248311, Heidelberg

Epworth Healthcare /ID# 248705, Richmond

American Oncology Partners of Maryland /ID# 244858, Bethesda

Duke Univ Med Ctr /ID# 242808, Durham

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 242754, Ann Arbor

Tulane University School of Medicine /ID# 244854, New Orleans

Hadassah Medical Center-Hebrew University /ID# 250484, Jerusalem

The Chaim Sheba Medical Center /ID# 250482, Ramat Gan

Tel Aviv Sourasky Medical Center /ID# 250483, Tel Aviv

Stanford University School of Med /ID# 242809, Stanford

Sylvester Comprehensive Cancer Center /ID# 243417, Miami

Mayo Clinic - Rochester /ID# 242844, Rochester

Memorial Sloan Kettering Cancer Center /ID# 243503, New York

Atrium Health Levine Cancer Institute /ID# 243420, Charlotte

Wake Forest Baptist Health /ID# 244252, Winston-Salem

University of Pennsylvania /ID# 242842, Philadelphia

Vanderbilt Ingram Cancer Center /ID# 242810, Nashville

Barts Health NHS Trust /ID# 248972, London